GLS and cancer: Since several oncogenes regulate GLS expression and many studies have shown that cancer cells are GLS-dependent3,9,10, GLS inhibitors (GLSi) (have been designed and evaluated in preclinical and clinical trials for brain tumors (trial ID: NCI-2018-00876)11–13.